Predictors of response and survival in cemiplimab–treated cutaneous squamous cell carcinoma: multicenter real-world evidence from Germany
In immunocompetent patients with advanced cSCC receiving PD-1 inhibition, BMI was prognostic for survival and AJCC stage remained the key driver of cSCC-specific mortality. Baseline LMR showed a modest association with response and differed between early- and advanced-stage disease, whereas other SIIBs were not consistently linked to tumor progression. Prospective validation is warranted.
Authors
- Stefanie Boms
- Jonas Rüth (ORCID: https://orcid.org/0009-0003-0315-1496)
- Nessr Abu Rached (ORCID: https://orcid.org/0000-0001-6853-0743)
- Sera S. Weyer-Fahlbusch (ORCID: https://orcid.org/0009-0009-9509-6271)
- Julia Hyun
- Laura Susok
- Jürgen C. Becker
- Thilo Gambichler
- Josefine Brune
- Alexander Kreuter
Institutions
- Witten/Herdecke University (DE)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Hospitals of the Ruhr-University of Bochum (DE)
- University Hospital Heidelberg (DE)
- Düsseldorf University Hospital (DE)
- HELIOS St. Elisabeth Klinik Oberhausen (DE)
- Klinikum Dortmund (DE)
- Klinikum Bielefeld (DE)
- St.-Johannes-Hospital Dortmund (DE)
- Katholisches Klinikum Bochum (DE)
- Klinikum Stuttgart (DE)
- Heinrich Heine University Düsseldorf (DE)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1007/s00432-026-06423-x
- Primary Topic
- Nonmelanoma Skin Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00